We found that GBM patients with the lowest overall survival had significantly higher levels of ATM expression, and that high-ATM expressing glioma patients had significantly shorter overall survival as compared to low-ATM expressing glioma patients. This evidence concerns the gene ATM and central nervous system cancer.